Genetic Landscape of Major Depressive Disorder : Assessment of Potential Diagnostic and Antidepressant Response Markers
© The Author(s) 2023. Published by Oxford University Press on behalf of CINP..
BACKGROUND: The clinical heterogeneity in major depressive disorder (MDD), variable treatment response, and conflicting findings limit the ability of genomics toward the discovery of evidence-based diagnosis and treatment regimen. This study attempts to curate all genetic association findings to evaluate potential variants for clinical translation.
METHODS: We systematically reviewed all candidates and genome-wide association studies for both MDD susceptibility and antidepressant response, independently, using MEDLINE, particularly to identify replicated findings. These variants were evaluated for functional consequences using different in silico tools and further estimated their diagnostic predictability by calculating positive predictive values.
RESULTS: A total of 217 significantly associated studies comprising 1200 variants across 545 genes and 128 studies including 921 variants across 412 genes were included with MDD susceptibility and antidepressant response, respectively. Although the majority of associations were confirmed by a single study, we identified 31 and 18 replicated variants (in at least 2 studies) for MDD and antidepressant response. Functional annotation of these 31 variants predicted 20% coding variants as deleterious/damaging and 80.6% variants with regulatory effect. Similarly, the response-related 18 variants revealed 25% coding variant as damaging and 88.2% with substantial regulatory potential. Finally, we could calculate the diagnostic predictability of 19 and 5 variants whose positive predictive values ranges from 0.49 to 0.66 for MDD and 0.36 to 0.66 for response.
CONCLUSIONS: The replicated variants presented in our data are promising for disease diagnosis and improved response outcomes. Although these quantitative assessment measures are solely directive of available observational evidence, robust homogenous validation studies are required to strengthen these variants for molecular diagnostic application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The international journal of neuropsychopharmacology - 26(2023), 10 vom: 19. Okt., Seite 692-738 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Priyanka [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 24.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ijnp/pyad001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351661964 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351661964 | ||
| 003 | DE-627 | ||
| 005 | 20231226051926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ijnp/pyad001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM351661964 | ||
| 035 | |a (NLM)36655406 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Priyanka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic Landscape of Major Depressive Disorder |b Assessment of Potential Diagnostic and Antidepressant Response Markers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of CINP. | ||
| 520 | |a BACKGROUND: The clinical heterogeneity in major depressive disorder (MDD), variable treatment response, and conflicting findings limit the ability of genomics toward the discovery of evidence-based diagnosis and treatment regimen. This study attempts to curate all genetic association findings to evaluate potential variants for clinical translation | ||
| 520 | |a METHODS: We systematically reviewed all candidates and genome-wide association studies for both MDD susceptibility and antidepressant response, independently, using MEDLINE, particularly to identify replicated findings. These variants were evaluated for functional consequences using different in silico tools and further estimated their diagnostic predictability by calculating positive predictive values | ||
| 520 | |a RESULTS: A total of 217 significantly associated studies comprising 1200 variants across 545 genes and 128 studies including 921 variants across 412 genes were included with MDD susceptibility and antidepressant response, respectively. Although the majority of associations were confirmed by a single study, we identified 31 and 18 replicated variants (in at least 2 studies) for MDD and antidepressant response. Functional annotation of these 31 variants predicted 20% coding variants as deleterious/damaging and 80.6% variants with regulatory effect. Similarly, the response-related 18 variants revealed 25% coding variant as damaging and 88.2% with substantial regulatory potential. Finally, we could calculate the diagnostic predictability of 19 and 5 variants whose positive predictive values ranges from 0.49 to 0.66 for MDD and 0.36 to 0.66 for response | ||
| 520 | |a CONCLUSIONS: The replicated variants presented in our data are promising for disease diagnosis and improved response outcomes. Although these quantitative assessment measures are solely directive of available observational evidence, robust homogenous validation studies are required to strengthen these variants for molecular diagnostic application | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Major depressive disorder | |
| 650 | 4 | |a antidepressants response | |
| 650 | 4 | |a diagnostic predictability | |
| 650 | 4 | |a genetic association studies | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 700 | 1 | |a Srivastava, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Guin, Debleena |e verfasserin |4 aut | |
| 700 | 1 | |a Thakran, Sarita |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Chandna, Puneet |e verfasserin |4 aut | |
| 700 | 1 | |a Sood, Mamta |e verfasserin |4 aut | |
| 700 | 1 | |a Chadda, Rakesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kukreti, Ritushree |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The international journal of neuropsychopharmacology |d 1995 |g 26(2023), 10 vom: 19. Okt., Seite 692-738 |w (DE-627)NLM097537578 |x 1469-5111 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:10 |g day:19 |g month:10 |g pages:692-738 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ijnp/pyad001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 10 |b 19 |c 10 |h 692-738 | ||